For example, BRAF inhibitors (BRAFi) (i.e. Vemurafenib, Dabrafenib) have been designed to block the BRAF kinase mutation V600E in melanoma (Karoulia et al 2017; Mayrhofer et al 2020; Röck et al 2019). Here, BRAF is linked to melanoma.